Nano-enabled pharmacogenomics: revolutionizing personalized drug therapy.

IF 3.6 4区 医学 Q2 ENGINEERING, BIOMEDICAL
Ruchi Tiwari, Dhruv Dev, Maharshi Thalla, Vaibhav Dagaji Aher, Anand Badrivishal Mundada, Pooja Anand Mundada, Krishna Vaghela
{"title":"Nano-enabled pharmacogenomics: revolutionizing personalized drug therapy.","authors":"Ruchi Tiwari, Dhruv Dev, Maharshi Thalla, Vaibhav Dagaji Aher, Anand Badrivishal Mundada, Pooja Anand Mundada, Krishna Vaghela","doi":"10.1080/09205063.2024.2431426","DOIUrl":null,"url":null,"abstract":"<p><p>The combination of pharmacogenomics and nanotechnology science of pharmacogenomics into a highly advanced single entity has given birth to personalized medicine known as nano-enabled pharmacogenomics. This review article covers all aspects starting from pharmacogenomics to gene editing tools, how these have evolved or are likely to be evolved for pharmacogenomic application, and how these can be delivered using nanoparticle delivery systems. In this prior work, we explore the evolution of pharmacogenomics over the years, as well as new achievements in the field of genomic sciences, the challenges in drug creation, and application of the strategy of personalized medicine. Particular attention is paid to how nanotechnology helps avoid the problems that accompanied the development of pharmacogenomics earlier, for example, the question of drug resistance and targeted delivery. We also review the latest developments in nano-enabled pharmacogenomics, such as the coupling with other nanobio-technologies, artificial intelligence, and machine learning in pharmacogenomics, and the ethical and regulatory aspects of these developing technologies. The possible uses of nanotechnology in improving the chances of pated and treating drug-resistant cancers are exemplified by case studies together with the current clinical uses of nanotechnology. In the last section, we discuss the future trends and research prospects in this dynamically growing area, stressing the importance of further advancements and collaborations which will advance the nano-enabled pharmacogenomics to their maximum potential.</p>","PeriodicalId":15195,"journal":{"name":"Journal of Biomaterials Science, Polymer Edition","volume":" ","pages":"1-26"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomaterials Science, Polymer Edition","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/09205063.2024.2431426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

The combination of pharmacogenomics and nanotechnology science of pharmacogenomics into a highly advanced single entity has given birth to personalized medicine known as nano-enabled pharmacogenomics. This review article covers all aspects starting from pharmacogenomics to gene editing tools, how these have evolved or are likely to be evolved for pharmacogenomic application, and how these can be delivered using nanoparticle delivery systems. In this prior work, we explore the evolution of pharmacogenomics over the years, as well as new achievements in the field of genomic sciences, the challenges in drug creation, and application of the strategy of personalized medicine. Particular attention is paid to how nanotechnology helps avoid the problems that accompanied the development of pharmacogenomics earlier, for example, the question of drug resistance and targeted delivery. We also review the latest developments in nano-enabled pharmacogenomics, such as the coupling with other nanobio-technologies, artificial intelligence, and machine learning in pharmacogenomics, and the ethical and regulatory aspects of these developing technologies. The possible uses of nanotechnology in improving the chances of pated and treating drug-resistant cancers are exemplified by case studies together with the current clinical uses of nanotechnology. In the last section, we discuss the future trends and research prospects in this dynamically growing area, stressing the importance of further advancements and collaborations which will advance the nano-enabled pharmacogenomics to their maximum potential.

纳米药物基因组学:个性化药物治疗的革命性变革。
将药物基因组学与纳米药物基因组学科学结合为一个高度先进的整体,催生了被称为纳米药物基因组学的个性化医疗。这篇综述文章涵盖了从药物基因组学到基因编辑工具的方方面面,以及这些工具在药物基因组学应用中的演变或可能演变,以及如何使用纳米颗粒传输系统传输这些工具。在这之前的工作中,我们探讨了药物基因组学多年来的演变、基因组科学领域的新成就、药物创制中的挑战以及个性化医疗策略的应用。我们特别关注纳米技术如何帮助避免药物基因组学早期发展过程中出现的问题,例如耐药性和靶向给药问题。我们还回顾了纳米药物基因组学的最新发展,如与其他纳米生物技术、人工智能和机器学习在药物基因组学中的结合,以及这些发展中技术的伦理和监管方面。通过案例研究和纳米技术目前的临床应用,说明了纳米技术在提高耐药性癌症的治愈率和治疗效果方面的可能用途。最后,我们讨论了这一蓬勃发展领域的未来趋势和研究前景,强调了进一步发展和合作的重要性,这将推动纳米药物基因组学发挥最大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biomaterials Science, Polymer Edition
Journal of Biomaterials Science, Polymer Edition 工程技术-材料科学:生物材料
CiteScore
7.10
自引率
5.60%
发文量
117
审稿时长
1.5 months
期刊介绍: The Journal of Biomaterials Science, Polymer Edition publishes fundamental research on the properties of polymeric biomaterials and the mechanisms of interaction between such biomaterials and living organisms, with special emphasis on the molecular and cellular levels. The scope of the journal includes polymers for drug delivery, tissue engineering, large molecules in living organisms like DNA, proteins and more. As such, the Journal of Biomaterials Science, Polymer Edition combines biomaterials applications in biomedical, pharmaceutical and biological fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信